Targeting the RSK Axis to Eliminate Medulloblastoma

Brain cancer is the second most prevalent cancer in children. Current treatment

options are chemotherapy, radiation, and surgery, which either prolongs the

child’s life for only two years or leaves them with negative side effects such as

slowed development. Thus, there is a pressing need for new therapeutics.

Mitacs Proposal Pambid, Mary

One of the focuses of our lab is to repurpose targeted therapies. The intern

narrowed down a list of drugs in clinical trials. One of the top leads, BI-D1870,

inhibits p90 ribosomal S6 kinase (RSK). We have demonstrated in breast cancer

that BI-D1870 significantly kills all cancer cells including the cells responsible for

relapse. It is thought that there is a set of cells in the bulk of the tumour that is left

over after treatment to reform a new tumour. We will apply this concept of RSK

inhibition to medulloblastoma.

In the research project, the intern will begin by determining the functional role of

RSK in medulloblastoma. Following this, we….

Faculty Supervisor:

Sandra Dunn

Student:

Partner:

Polytechnique Montréal;Hannah's Heroes Foundation

Discipline:

Life Sciences

Sector:

Other services (except public administration)

University:

The University of British Columbia

Program:

Accelerate

Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Government

International

Load More

International

Load More